The MONARCH-2 study was a global phase III, randomised (2:1), double-blind clinical trial which included 669 pre-, peri- (with ovarian suppression), and postmenopausal women with advanced breast cancer, positive hormone receptors, and HER-2 negative, who were resistant to endocrine therapy. This evidence concerns the gene NR4A1 and breast cancer.